Aclaris Therapeutics ACRS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $28.66M+43.6% | $19.96M-21.0% | $25.26M-0.6% | $25.4M-16.3% | $30.36M+23.6% | ||
| $76.76M+8.4% | $70.79M+0.2% | $70.66M-5.0% | $74.4M-0.7% | $74.96M-15.8% | ||
| $110.23M+14.4% | $96.32M-4.3% | $100.59M-3.5% | $104.2M-4.2% | $108.79M-13.6% | ||
| $750K-1.4% | $761K-6.2% | $811K-6.6% | $868K-7.9% | $942K-6.5% | ||
| $198.72M+23.8% | $160.46M-8.6% | $175.53M-7.2% | $189.15M-4.5% | $198.09M-10.1% | ||
| $14.73M+12.0% | $13.16M+43.2% | $9.19M+4.4% | $8.8M+38.4% | $6.35M+35.5% | ||
| $3.97M+0.7% | $3.94M+0.5% | $3.93M+0.3% | $3.91M— | —— | ||
| $27.37M-4.5% | $28.65M+11.8% | $25.63M-4.5% | $26.84M+24.8% | $21.51M-31.9% | ||
| $55.07M-4.0% | $57.38M+3.5% | $55.43M-3.4% | $57.41M+6.3% | $54.03M-16.6% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| -$987.61M-2.0% | -$967.78M-2.1% | -$947.99M-1.6% | -$933.38M-1.7% | -$917.95M-1.7% | ||
| $143.65M+39.4% | $103.08M-14.2% | $120.1M-8.8% | $131.74M-8.6% | $144.07M-7.4% | ||
| $198.72M+23.8% | $160.46M-8.6% | $175.53M-7.2% | $189.15M-4.5% | $198.09M-10.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aclaris Therapeutics's total assets?
- Aclaris Therapeutics (ACRS) holds $198.7M in total assets, up 0.3% year over year.
- How much debt does Aclaris Therapeutics have?
- Aclaris Therapeutics carries $2.0M in total debt against $143.6M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Aclaris Therapeutics have?
- Aclaris Therapeutics holds $28.7M in cash and equivalents.
- Can Aclaris Therapeutics cover its short-term obligations?
- Its current ratio is 4.03 — current assets exceed current liabilities.
- Where does Aclaris Therapeutics's balance sheet data come from?
- Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
